α-Glucosidase inhibitors in the treatment of diabetes

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 1, 1997, Pages 48-55

  Tan, Meng Hee ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002263122     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199702000-00007     Document Type: Article

References (52)

1. Expert Committee of the Canadian Diabetes Advisory Board: Clinical practice guidelines for treatment of diabetes mellitus. Can Med Assoc J 1992, 147:697-712.
2. Jenkins DJA, Josse RG, Jenkins AL, Wolever TMS, Vuksan V: Implications of altering the rate of carbohydrate absorption from the gastrointestinal tract. Clin Invest Med 1995, 18:296-302. A good review of the various approaches that can be used in modulating the digestion and absorption of carbohydrates.
3. Newcomer AD, McGill DB: Distribution of disaccharidase activity in the small bowel of normal and lactase deficient subjects. Gastroenterology 1966, 51:481-488.
4. Balfour JA, McTavish D: Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993, 46:1025-1054.
5. Bischoff H: The mechanism of α-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995, 18:303-311.
6. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TMS: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diab Care 1996, 19:1190-1193.
7. Raptis S, Dimitradis G, Karaiskos K, Rosenthal J, Zoupas C, Moulopoulos S: The effects of acarbose treatment on release of pancreatic and gastrointestinal hormones in man. In Proceedings of First International Symposium on Acarbose, Montreux, October, 1982. Edited by Creutzfeldt W. Amsterdam: Excerpta Medica; 210-215.
8. Uttenthal LO, Ukponmwam OO, Chiglione M, Bloom SR: Acute short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man. Dig Dis Sci 1987, 32:139-144.
9. Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lucker PW: Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995, 56:493-501.
10. Goke B, Hermann C, Goke R, Fehmann HC, Berghofer P, Richter G, Arnold R: Intestinal effects of α-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994, 24(suppl 3):25-30.
11. Chiasson JL, Jasse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994, 121:928-935.
12. Coniff RF, Shapiro JO, Seaton TB, Bray GA: Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutarnide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995, 98:443-451. Documentation of the efficacy and safety of acarbose.
13. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA: A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995, 18:928-932. Documentation of the efficacy and safety of acarbose.
14. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB: Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: a placebo-controlled dose-comparison study. Diabetes Care 1995, 18:817-824. Documentation of the efficacy and safety of acarbose.
15. May C: Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM), treated with sulphonylureas. Diabetes Und Stoffwechsel 1995, 4:3-8.
16. Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the Essen study. Diabetes Care 1994, 17:561-566.
17. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ, et al.: Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabete Metab 1995, 21:256-260.
18. Vannasaeng S, Ploybutr S, Nitiyanant W, Peerapatdit T, Vichayanrat A: Effects of α-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus. J Med Assoc Thai 1995, 78:578-585.
19. Kingma PJ, Menheere PPCA, Sels JP, Nieuwenhuijzen Kruseman AC: α-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 1992, 15:478-483.
20. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A: Effects of the carbohydrate inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994, 17:20-29.
21. Pagano G, Marena S, Corgiat-Mansin L, et al.: Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabete Metab 1995, 21:162-167.
22. Marena S, Tagliaferro V, Cavallero G, Pagani A, Montegrosso G, Bianchi W, Zaccarini P, Pageno G: Double-blind crossover study of acarbose in type I diabetic patients. Diabet Med 1991, 8:674-678.
23. Dimitriadis GD, Hatziagellaki E, Alexopoulos E, Kordonouri O, Komesidou V, Ganotakis M, Raptis S: Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus. Diabetes Care 1991, 14:393-398.
24. Tattersall R: A-glucosidase inhibition as an adjunct to the treatment of type I diabetes. Diabet Med 1993, 10:688-693.
25. Rios MS: Acarbose and insulin therapy in type I diabetes mellitus. Eur J Clin Invest 1994, 24(suppl 3):36-39.
26. Escobar JF, de-Leiva A, Pinton F, et al.: Clinical effectiveness and tolerance of acarbose in the treatment of insulin-dependent diabetic patients (type I). Med Clin (Barc) 1993, 100:488-491.
27. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ: Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled on sulfonylureas. Diabetes Care 1990, 13(suppl 3):32-36.
28. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y: Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 1996, 45:731-737. Evidence that voglibose improves insulin sensitivity.
29. Leonhardt W, Hanefeld M, Fischer S, Schulze J: Efficacy of α-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidemia. Eur J Clin Invest 1994, 24:45-49.
30. Nestel PJ: Lower triglyceride production with carbohydrate-rich diet during treatment with acarbose [abstract]. In Acarbose for Treatment of Diabetes Mellitus. Edited by Creutzfeldt W. Berlin: Springer-Verlag; 1988:68.
31. Hegele RA, Connelly PW, Palmason C, Jenkins DJA, Wolever TMS: Differential response of plasma lipoprotein(a) and apolipoprotein B in NIDDM subjects treated with acarbose. Diabetes Care 1995, 18:272-273.
32. Wolever TMS, Radmard R, Chiasson JL, Hunt JA, Josse RG, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH: One-year acarbose treatment raises fasting serum acetate in diabetic patients. Diabet Med 1995, 12:164-172.
33. Hollander P: Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992, 44(suppl 3):47-53.
34. Spengler M, Cagatay M: The use of acarbose in the primary-care setting: evaluation of efficacy and tolerabllity of acarbose by postmarketing surveillance study. Clin Invest Med 1995, 18:325-331.
35. Van-Gaal L, Nobels F, De-Leeuw I: Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Z Gastroenterol 1991, 29:642-644.
36. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, Lefebvre PJ: Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994, 24(suppl 3):50-54.
37. Gerard J, Lefebvre PJ, Luyckx AS: Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Pharmacol 1984, 27:233-236.
38. Hillebrand I, Graefe KH, Bischoff H, Frank G, et al.: Serum digoxin and propranolol levels during acarbose treatment. Diabetologia 1981, 21:282.
39. Product monograph (Precose, Bayer Pharmaceutical Division, West Haven, CT).
40. Okada S, Ishii K, Tanokuchi S, Hamada H, Ichiki K, Ota Z: No effect of an α-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus and low function of pancreatic β cells. J Intern Med Res 1995, 23:294-298.
41. McCullouch DK, Kurtz AB, Tattersall RB: A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosldase inhibition. Diabetes Care 1983, 6:483-487.
42. Toeller M: Nutritional recommendations for diabetic patients and treatment with α-glucosidase inhibitors. Drugs 1992, 44:13-20.
43. Acarbose for diabetes mellitus. Med Lett Drugs Ther 1996, 38:9-10. Brief review of the cost of drugs in treating NIDDM patients.
44. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
45. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
46. Chakrabarti S, Cherian PV, Sima AA: The effect of acarbose on diabetes- and age-related basement membrane thickening in retinal capillaries of the BB/W-rat. Diabetes Res Clin Pract 1993, 20:123-128.
47. Cohen MP, Klepser H, Wu VY: Effect of alpha-glucosidase inhibition on nonenzymatic glycation of glomerular basement membrane. Gen Pharmacol 1991, 22:515-519.
48. Sima AA, Chakrabarti S: Long-term suppression of post-prandial hyperglycemia with acarbose retards the development of neuropathies in the BB/W-rat. Diabetologia 1992, 35:325-330.
49. Taylor H: Post-prandial hyperglycaemia and diabetic complications. Pract Diabetes 1993, 10(suppl):10-14.
50. Keen H: Glucomodulation: a new therapeutic approach. Pract Diabetes 1993, 10(suppl):5-9.
51. Lebovitz HE: Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs 1992, 44(suppl 3):21-28.
52. Folsch UR: Clinical experience with acarbose as first line therapy in NIDDM. Clin Invest Med 1995, 18:312-317.